{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-023124","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.878511+00:00","generated_at":"2026-06-13T19:15:47.523251+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Foghorn Therapeutics announces 2023 annual meeting results; all director nominees elected and auditor ratified","bullets":["Douglas Cole elected with 19,470,509 for, 2,142,125 against; Gill elected with 21,481,572 for, 144,160 against.","Parshall elected with 21,600,133 for, 25,599 against; there were 9,648,103 broker non-votes on director election.","Ratification of Deloitte & Touche as auditor passed with 31,282,179 for, 858 against, 9,849 abstentions."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-023124","json":"https://secwatch.observer/filing/0001628280-23-023124.json","markdown":"https://secwatch.observer/filing/0001628280-23-023124.md","text":"https://secwatch.observer/filing/0001628280-23-023124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023023124/0001628280-23-023124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023023124/fhtx-20230621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:15:47.523251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6897d7f22af663703127e69b5481136d51b38cd","claim":"Foghorn Therapeutics Inc. shareholders approved Election of three Class III directors at the 2023-06-21 meeting.","evidence_excerpt":"Director Nominee Votes For Votes Against Abstentions Douglas G. Cole, M.D. 19,470,509 2,142,125 32,149 Balkrishan (Simba) Gill, Ph.D. 21,481,572 144,160 19,051 B. Lynne Parshall 21,600,133 25,599 19,051 There were 9,648,103 broker non-votes regarding the election of directors.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023023124/0001628280-23-023124-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"ae6e955912afa3d90d675265f7fbb2d7b5d3f01a","claim":"Foghorn Therapeutics Inc. shareholders approved Ratification of selection of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-21 meeting.","evidence_excerpt":"Stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the voting included 31,282,179 votes for, 858 votes against and 9,849 abstentions. There were no broker non-votes regarding this proposal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023023124/0001628280-23-023124-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}